Pioneers in Engineering Biology. Veterans of the diagnostic industry. Disease experts.

Julie Garlikov is the Chief Commercial Officer at Sherlock Biosciences. A global marketing and sales expert, Julie joins Sherlock with more than 20 years of experience in consumer product commercialization, accelerating growth for digital consumer health, wellness and beauty brands.

Prior to Sherlock, Julie was vice president of marketing at Grail, where she helped define the market for the first multi-cancer early detection blood screening test, Galleri®, and transformed the digital product experience for employer and patient-initiated telemedicine channels. Over her career, Julie has held leadership roles at organizations including Rodan + Fields, Allergan, PepsiCo, Johnson & Johnson and Procter & Gamble, where she honed her expertise scaling brands through a disciplined approach to marketing, sales, product and commercialization to drive long-term growth.

Julie earned her MBA in Marketing from Columbia School of Business and a B.A. in Anthropology from the University of California, Berkeley.

Karen Davies is the Chief Development Officer at Sherlock Biosciences. A medical diagnostic and device development veteran, Karen joins Sherlock with more than 30 years of experience driving innovation across a broad spectrum of diagnostic platforms.

Prior to Sherlock, Karen was at Quidel, where she served as vice president of instrument systems and was responsible for product architecture and development, as well as vice president of business transformation, where she was responsible for internal process improvement and global commercial communications associated with M&A transactions. Over her career, Karen has held key leadership roles at organizations including Gen-Probe, Abbott and Dura Pharmaceuticals, serving as part of the launch team for multiple diagnostic platforms, from the central lab to point-of-care and over the counter to consumers.

Karen holds a Bachelor of Science degree in Mechanical Engineering from Stanford University.

Heather Youngs is Program Officer for Scientific Research at Open Philanthropy, where she co-manages a portfolio of grants and investments with the aim of “doing as much good as possible” in underfunded areas. She is also a founding director at Redleaf Biologics and a partner in Ninole Cacao.

Prior to joining Open Philanthropy, Heather was director of the Bakar Fellows Program for faculty entrepreneurs at UC Berkeley, a senior strategic advisor at the Energy Biosciences Institute at UC Berkeley and an assistant professor at Michigan Technological University.

She received a B.S. in biology from Michigan Technological University, a Ph.D. in biochemistry and molecular biology from Oregon Health and Science University, and was an NIH post-doctoral fellow at Stanford University.

Paul Meister is a partner at Novalis LifeSciences and co-founder of Liberty Lane Partners, a private investment company. He serves as Chairman of Arbor Biotechnologies and Amneal Pharmaceuticals, and is on the board of Ori Biotech, Mercy BioAnalytics and several other early-stage life science and diagnostic companies.

Paul previously served as Chairman of Thermo Fisher Scientific and Vice Chairman of Fisher Scientific International. He also served as Chairman and CEO of inVentiv Health (now Syneos Heath.)

Paul earned a MBA from Northwestern University and a B.A. from the University of Michigan, and serves on the board of Michigan’s Life Sciences Institute.

Greg Dale is the vice president, engineering and product development at Sherlock Biosciences. Dale’s career spans over 25 years’ experience in medical device, in-vitro diagnostics and microfluidic products.

Prior to joining Sherlock, Greg was at General Fluidics Corporation, where he served as vice president of engineering and was responsible for development of a clinical chemistry platform. Greg has held roles in research and development, engineering, software, manufacturing and quality assurance while at organizations including Qiagen, Emulate, Ciba Vision, Senseonics, and Canon, where he has developed products including DNA sequencers, implantable glucose sensors, wearable medical devices, high-volume lab automation and IVD platforms.

Greg received a B.S. degree in Mechanical Engineering from Virginia Tech and is an inventor on over 35 issued patents.

Sophie Chapelle joins Sherlock with more than 20 years of experience building biopharma and diagnostics businesses through strategic relationships with clients, distributors, suppliers and academic partners.

Sophie has deep commercialization expertise including sales and marketing, deal making, alliance management, technology licensing, operational delivery, strategic planning and financial management. She honed her expertise working in roles of increasing responsibilities in several high growth medical technology and pharmaceutical companies including Scipher Medicine, where she served as Chief Commercial Officer and was responsible for building the company’s first autoimmune precision medicine diagnostics and drug target discovery platform. Prior to Scipher, Sophie was President, Clinical Trials at CogState, where she led the division to profitability and best vendor status with leading neuroscience pharmaceutical companies. Before that, Sophie was Associate Director, Worldwide Business Development at Pfizer, where she was responsible for in-sourcing and managing delivery of external clinical technology platforms. Sophie started her career in sales with UCB, where she grew from technical support associate to Head of Global Marketing & Sales for its biologics contract manufacturing division.

Sophie earned her engineering degree from University of Brussels (ULB, Belgium) and her masters in medicinal chemistry from University of Lille (France). Sophie also holds a degree in executive business management from Columbia University.

James Scavone is the vice president of finance and controller at Sherlock Biosciences. James brings more than 20 years of experience in finance and operations, focused on scaling the financial operations for emerging and established life sciences companies. Overseeing Sherlock’s finance and accounting operations, James provides critical financial analysis to support Sherlock’s strategic goals, while also providing results-driven leadership to build company infrastructure and systems to support growth across all departments.

James joins Sherlock from bluebird bio, where he led financial operations and oversaw system setups and integrations. Prior to bluebird bio, Jim served in accounting roles of increasing responsibility at Merrimack Pharmaceuticals, where he ascended to the position of manufacturing controller, overseeing production system setups and ongoing operations for the launch of commercially approved products.

James holds a Bachelor of Sciences in Business Administration with a concentration in accounting from University of New Hampshire Peter T. Paul College of Business and Economics.

Dr. Bryan Dechairo is the chief executive officer of Sherlock Biosciences and also serves on the company’s Board of Directors. Bryan joins Sherlock with more than 20 years of experience developing and commercializing revenue generating clinical innovations that improve patient lives.

Prior to Sherlock, Bryan served as executive vice president of clinical development at Myriad Genetics, where he oversaw the development portfolio, delivering business-critical evidentiary data for value-based reimbursement and market acceptance of commercial and novel diagnostic products across six business units globally. Before joining Myriad, he was chief medical officer, chief scientific officer and senior vice president of research and development at Assurex Health, which was acquired by Myriad in 2016. During his extensive career, Bryan held roles of increasing responsibility at Medco, Pfizer, Oxagen, Sequana and Roche, where he established a proven track record of funding and scaling business from venture backed start-ups to profitable fortune 50 public companies.

Bryan has authored more than 50 academic and research-based publications, and earned a Ph.D. in Common Complex Human Genetics from the Institute of Child Health at University College London and a B.A. in Integrative Biology from the University of California, Berkeley.

Dr. Deborah Hung works at the interface of chemical biology, genomics, and bacterial pathogenesis to establish new paradigms for an antibiotic based on the essential biology required for a pathogen to cause disease within the host. Using her training as a synthetic chemist, bacterial geneticist, and clinical physician, she explores approaches to disrupting the pathogen-host interaction.

Dr. Hung is a physician-scientist at the Broad Institute of MIT and Harvard, the Department of Molecular Biology at the Massachusetts General Hospital, and the Department of Genetics at Harvard Medical School, and is the Co-Director of the Infectious Disease and Microbiome Program at the Broad Institute. She is an attending physician at the Brigham and Women’s Hospital in Boston in infectious diseases and critical care medicine.

Pardis Sabeti M.D., Ph.D., is a professor at the Center for Systems Biology and Department of Organismic and Evolutionary Biology at Harvard University and the Department of Immunology and Infectious Disease at the Harvard School of Public Health, an Institute Member of the Broad Institute of Harvard and MIT, and an investigator of the Howard Hughes Medical Institute.

Her computational genomic lab has contributed to widely varying fields — including human evolutionary biology, viral sequencing, information theory, rural disease surveillance, and education efforts in West Africa. The lab aims to create comprehensive approaches for detecting, containing, and treating deadly infectious diseases, including Lassa virus, Ebola virus, Zika virus, and Babesiosis microtia. Dr. Sabeti has invested in capacity building and education throughout the continent, enabling the first diagnoses of Ebola in Sierra Leone and Nigeria, training over 70 African scientists through summer-long educational programs, and establishing genome centers in West Africa.

Born in Tehran, Dr. Sabeti immigrated to the United States at the age of two. She completed her undergraduate degree in biology at MIT and her doctorate at Oxford University as a Rhodes Scholar. After that, she obtained her medical degree summa cum laude from Harvard Medical School as a Soros Fellow. Dr. Sabeti has received numerous awards and honors including World Economic Forum (WEF) Young Global Leader, National Geographic Emerging Explorer, Smithsonian American Ingenuity Award for Natural Science, TIME’s “Person of the Year” as one of the Ebola fighters, and TIME’s “100 Most Influential.”

She is also the host of “Against All Odds,” which is included as part of the AP Statistics curriculum nationwide, and is the lead singer of the rock band Thousand Days.

David R. Walt, Ph.D., is an internationally recognized expert in nanoscience and diagnostics. He is the Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard Medical School, a core faculty member of the Wyss Institute at Harvard University, a professor of pathology at Brigham and Women’s Hospital, and a Howard Hughes Medical Institute Professor. Previously, Dr. Walt was University Professor at Tufts University, where he was a faculty member in the chemistry department. Dr. Walt is the scientific founder of Illumina Inc., where he served on the board for 18 years, and Quanterix Corporation. He co-founded several other life sciences startups, including Ultivue, Inc., and Arbor Biotechnologies. His laboratory was the first to introduce the idea of digital protein detection by developing a high throughput technology for performing single molecule analysis.

Dr. Walt has published more than 350 peer-reviewed papers and has over 100 U.S. patents. He has received numerous national and international awards and honors for his fundamental and applied work in the field of optical microwell arrays and single molecules. In addition to fundamental work on single molecules, Dr. Walt’s lab focuses on solving important clinical problems in areas that lack available biomarkers due to the inadequate sensitivity of existing assay technologies.

Dr. Walt is a member of the National Academy of Engineering and the National Academy of Medicine, and a Fellow of the American Academy of Arts and Sciences, the American Institute for Medical and Biological Engineering, and the National Academy of Inventors. He received a B.S. in chemistry from the University of Michigan and a Ph.D. in chemical biology from SUNY at Stony Brook. Dr. Walt completed his postdoctoral studies at MIT.

Jim Collins, Ph.D., is the Termeer Professor of Medical Engineering & Science and professor of Biological Engineering at MIT, as well as a member of the Harvard-MIT Health Sciences & Technology faculty. He is also a core founding faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University, and an Institute Member of the Broad Institute of MIT and Harvard.

Dr. Collins is one of the founders of the field of synthetic biology, and his research group is currently focused on using synthetic biology to create next-generation diagnostics and therapeutics. Dr. Collins’s patented technologies have been licensed by over 25 biotech, pharmaceutical, and medical device companies, and he has helped launch a number of companies, including Synlogic and Senti Biosciences.

He has received numerous awards and honors, including a Rhodes Scholarship, a MacArthur “Genius” Award, an NIH Director’s Pioneer Award, the Sanofi-Institut Pasteur Award, as well as several teaching awards. Dr. Collins is an elected member of the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Medicine as well as the American Academy of Arts & Sciences, the National Academy of Inventors, and the World Academy of Sciences.

Dr. Collins received a B.A. from the College of the Holy Cross in 1987 and a Ph.D. in 1990 from the University of Oxford.

Michael P. Rubin, M.D., Ph.D. is the founder and CEO of Northpond Ventures, a formative stage venture capital fund dedicated to science and technology. Dr. Rubin’s active directorships include Mitra Biotech, DiCE Molecules, Inflammatix, Teckro, Candel, and SpeedDx. Dr. Rubin was previously co-founder and managing partner of Sands Capital Ventures, a global cross industry venture capital business, and affiliate of Sands Capital Management. Under Dr. Rubin’s leadership, SCV invested in dozens of leading startups, resulting in numerous successful businesses and exists, including but not limited to Complete Genomics (IPO), Dova (IPO), Quad Technologies (sale to Biotechne), Firefly Bioworks (sale to Abcam), and Agilis (Sale to PTC Therapeutics).

Dr. Rubin became a board-certified physician and surgeon, and completed his fellowship training at Harvard Medical School. Dr. Rubin has led multiple IRB-approved research groups, published numerous papers in refereed journals, written chapters in leading texts, conducted clinical trials on leading commercial molecules, received NIH funding for novel research, attained industry sponsored funding for original biotherapeutic investigations, presented studies at large international forums, and conducted basic science research in molecular genetics at Harvard’s Ocular Genetics Institute. Dr. Rubin also holds an MBA from The University of Massachusetts Amherst, is a CFA charterholder, earned his medical doctorate at The University of Chicago, and holds a B.S. in Electrical Engineering from The UCLA Samueli School of Engineering, where he was the student graduation speaker.

Kristin Riley comes to Sherlock with over 15 years of experience in diagnostics with functional expertise ranging from R&D and operations to global product management. While at IDEXX Laboratories, she led the analytical chemistry, technology transfer and manufacturing scale-up lab, which brought more than 40 products to the veterinary and environmental diagnostics markets, earning her the technical achievement award for her work in high-throughput process development automation. As a global product leader, Kristin also drove the strategic direction and operational execution for the preclinical biomarkers business. Prior to IDEXX, Kristin managed the proteomics and lipidomics core services at the Maine Medical Center Research Institute.

Kristin graduated summa cum laude with a BS in chemistry from Hobart and William Smith Colleges, an MS in biophysical chemistry from Yale University and an MBA from MIT Sloan School of Management.She has served on the Board of Directors and as Vice President for the Cape Elizabeth Education Foundation, supporting innovative grants for student curricula. Kristin also served as co-chair of the Women’s Executive Leadership Group while at MIT and most recently, she became a founding member of the Boston chapter of Chief, a network focused on supporting women in executive leadership roles.

Amy Lyons is the VP of Marketing at Sherlock Biosciences.  Amy comes to Sherlock with more than 20 years of experience driving impactful strategic communications programs for clients in the B2B technology, healthcare, consumer and non-profit industries. Driving Sherlock’s external and internal communications programs, Amy provides leadership and strategic oversight to media relations, social media, clinical communications, investor relations and internal communications activities.

Prior to joining Sherlock Biosciences, Amy served as Managing Partner of SHIFT Communications. At SHIFT she executed the Agency’s strategic direction across talent, business development, client service and financial management. She also worked with Agency clients, providing leadership and counsel in the areas of crisis communications, corporate messaging and branding, content development and media strategy.

Recognized by PR News as a “Top Woman in PR” and by PR Week as a “Champion of PR,” Amy brings a keen understanding of the communications discipline and operational excellence needed to drive a high-impact communications program. Amy graduated with a Bachelor of Arts from Hollins University and received her Masters Degree at Virginia Commonwealth University. She’s served as a member of The Boston Chamber of Commerce’s Women’s Network Advisory Board and volunteers her time with The Ronald McDonald House Charities of Eastern New England.

Tiffany Summerville is the VP of Human Resources at Sherlock Biosciences. A seasoned human resources strategist with more than 20 years of experience in the pharmaceutical industry, Tiffany is committed to marrying a business strategy with employee development.  Tiffany understands how human resources impacts an organization’s bottom line and has a track-record of building high-performance organizations with exceptional cultures.

Most recently, Tiffany served as the Director of Human Resources at  Acorda Therapeutics, Inc., where she was responsible for all aspects of HR including employee relations, learning and development, benefits, performance management, leadership development strategy, and diversity and inclusion program development. Prior to Acorda Therapeutics, Tiffany led talent acquisition efforts at Barr Pharmaceuticals and Alternative Resources Company, where she developed broad expertise in all aspects of the recruitment life-cycle from candidate sourcing and onboarding through retention strategies and leadership development.

Tiffany obtained her Bachelor of Science in Communications with a minor in Marketing from one of the oldest Historically Black Colleges and Universities (HBCU), Bowie State University, and is a proud member of Alpha Kappa Alpha Sorority, Incorporated. She also serves as the President of the professional association, Women of Color in Corporate America. Tiffany holds numerous human resource certifications and accreditations, as well as memberships in the Society for Human Resource Management and the American Society for Training and Development.